Market Access What the low impact of Humira biosimilars teaches us about d... Almost everyone seems to agree that drug prices are too high.
Views & Analysis Harmonised health technology assessment in Europe? There's a... Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture
Views & Analysis NICE numbers: trends in recommendations should prompt a revi... Should there be a different review of NICE as part of a successor PPRS?
Views & Analysis Balancing cost:benefit in ‘well-treated’ malignancies The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
Views & Analysis Accessing biosimilars: untapped potential in EU and US Though they can reduce the costs of health care, biosimilars still face challenges to access.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
